In the fiercely competitive global stent market, Abbott seems to view size as mattering most.
The law includes safeguards, including requirements that terminally ill patients ask for the requisite drugs three times before they're actually dispensed.
Having failed so far to get its extended-release Parkinson's drug Rytary to market, Impax Laboratories ($IPXL) is turning to asking three big-name specialists what it should do.
The U.K.'s cost-effectiveness police have been arresting Roche's Avastin development efforts once again. As Cover magazine reports, the National Institute for Health and Clinical Excellence has nixed two proposed uses for the drug in ovarian cancer, one of the hardest-to-treat forms of the disease.
Impax Laboratories is bringing in the big guns to help it accomplish what it has been unable to do on its own.
According to AdvaMed, the user fees that industry players contribute to the FDA, money that currently helps the agency retain staff and support programs, may now take a hit to the tune of about $2.9 million.
The lengthy patent dispute between Medtronic and Boston Scientific will end in the nation's highest courtroom, as the Supreme Court has agreed to hear Medtronic's plea to avoid paying cardiac device royalties.
Covidien nailed down a 510(k) clearance, this time for a group of next-generation Nellcor pulse oximetry monitoring devices--a regulatory win that will likely help fuel continued robust growth in the line.
Medtronic snagged a CE mark for the Export Advance aspiration catheter, planning to launch the clot-removing device in Europe and other international markets.
In April, Abbott Laboratories announced it was yanking the FreeStyle InsuLinx blood glucose meters off the U.S. market, and now the FDA has assigned its most-serious Class I label to the effort, warning that the devices' malfunction could lead to serious injury or death.